Please login to the form below

Scottish Medicines Consortium

This page shows the latest Scottish Medicines Consortium news and features for those working in and with pharma, biotech and healthcare.

Novartis gets EU nod for Luxturna gene therapy

therapy” and that decisions from national reimbursement bodies – including NICE and the Scottish Medicines Consortium – “are expected in 2019 and 2020.”.

Latest news

Daily Brief: DeepMind and NHS success in AI, Bayer invests in COPD, Alecensa OK in Scotland

Roche’s Alecensa approved by Scottish Medicines Consortium. Patients in Scotland with untreated, advanced non-small-cell lung cancer (NSCLC) with ALK-positive tumours have a new treatment option available via ... The positive decision from the Scottish
Daily Brief: Resignation throws Brexit into disarray, Celgene exec joins Orchard board, Scotland rules on EUSA drug

EUSA’s Fotivda approved for NHS use in Scotland. Specialist pharma company EUSA Pharma has welcomed the Scottish Medicines Consortium approval of its renal cell carcinoma treatment Fotivda (tivozanib).
UK, Germany back routine use of J&J’s Tremfya

The National Institute for Health and Care Excellence (NICE) for England and Wales, the Scottish Medicines Consortium (SMC) and Germany’s Federal Joint Committee (G-BA) are the first health technology
Merck and Pfizer set to win NICE backing for Bavencio

The pharma giants are expecting final guidance from NICE within the next coming weeks, and a decision by the Scottish Medicines Consortium (SMC) is also expected.
NICE reverses its rejection of Eisai’s Lenvima

This particular subset of patients in Scotland and Wales can already access Eisai’s medicine due to approvals from the Scottish Medicines Consortium (SMC) and the All Wales Medicines Strategy. ... The positive recommendation comes three years after the

More from news
Approximately 4 fully matching, plus 80 partially matching documents found.

Latest Intelligence

The reality of real-world evidence

Zaltrap re-submission to the Scottish Medicines Consortium (SMC) included RWE (pooled data from two open-label, single-arm studies) to demonstrate prolonged safety and QoL benefit.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Senior Director – Healthcare PR – Global Agency: Salary TBC

Senior Account Director development role to Business Director, H...: Excellent package

Account Director – Healthcare Marketing – Berks: Salary TBC

Engagement Expert, Healthcare Brand Communications, London: Excellent package

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Account Director, Healthcare Marketing Agency: Salary TBC

Account Director – Health Policy – Global Agency: Salary TBC

Senior Account Manager, Rare Diseases – Medical Communications, ...: Excellent package

Global Business Development Director – Health Education: excellent commission

Account Manager / Senior Account Manager: 35, 000-40, 000

Account Manager / Account Director: Competative

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Account Director: Competitive Salary Offered

Associate Director: £75, 000-90, 000

Medical Writer: Salary TBC

Client Services Director – Medical Education Agency – North West...: Salary TBC

Home-based Senior Project Manager – Independent Med Ed: Salary TBC

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Account Director, Medical Education: Salary TBC

Senior Account Manager: Competitive Salary Offered

Business Director: Competitive Salary Offered

Senior Medical Writer: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Healthcircle

We're Healthcircle – an award-winning healthcare advertising and creative communications agency, offering a holistic approach to brand health. With a...

Latest intelligence

The UK’s new five-year pricing agreement: Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape: Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch: ...